Pablo Vivas to Cisplatin
This is a "connection" page, showing publications Pablo Vivas has written about Cisplatin.
Connection Strength
1.232
-
Reyes-Gonz?lez JM, Armaiz-Pe?a GN, Mangala LS, Valiyeva F, Ivan C, Pradeep S, Echevarr?a-Vargas IM, Rivera-Reyes A, Sood AK, Vivas-Mej?a PE. Targeting c-MYC in Platinum-Resistant Ovarian Cancer. Mol Cancer Ther. 2015 Oct; 14(10):2260-9.
Score: 0.505
-
Echevarr?a-Vargas IM, Valiyeva F, Vivas-Mej?a PE. Upregulation of miR-21 in cisplatin resistant ovarian cancer via JNK-1/c-Jun pathway. PLoS One. 2014; 9(5):e97094.
Score: 0.465
-
B?ez-Vega PM, Echevarr?a Vargas IM, Valiyeva F, Encarnaci?n-Rosado J, Roman A, Flores J, Marcos-Mart?nez MJ, Vivas-Mej?a PE. Targeting miR-21-3p inhibits proliferation and invasion of ovarian cancer cells. Oncotarget. 2016 Jun 14; 7(24):36321-36337.
Score: 0.134
-
Moreno-Smith M, Halder JB, Meltzer PS, Gonda TA, Mangala LS, Rupaimoole R, Lu C, Nagaraja AS, Gharpure KM, Kang Y, Rodriguez-Aguayo C, Vivas-Mejia PE, Zand B, Schmandt R, Wang H, Langley RR, Jennings NB, Ivan C, Coffin JE, Armaiz GN, Bottsford-Miller J, Kim SB, Halleck MS, Hendrix MJ, Bornman W, Bar-Eli M, Lee JS, Siddik ZH, Lopez-Berestein G, Sood AK. ATP11B mediates platinum resistance in ovarian cancer. J Clin Invest. 2013 May; 123(5):2119-30.
Score: 0.108
-
Mangala LS, Zuzel V, Schmandt R, Leshane ES, Halder JB, Armaiz-Pena GN, Spannuth WA, Tanaka T, Shahzad MM, Lin YG, Nick AM, Danes CG, Lee JW, Jennings NB, Vivas-Mejia PE, Wolf JK, Coleman RL, Siddik ZH, Lopez-Berestein G, Lutsenko S, Sood AK. Therapeutic Targeting of ATP7B in Ovarian Carcinoma. Clin Cancer Res. 2009 Jun 01; 15(11):3770-80.
Score: 0.021